Senseonics (NYSEAMERICAN:SENS) Lowered to “Hold” at Zacks Investment Research

Senseonics (NYSEAMERICAN:SENSGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday, Zacks.com reports.

According to Zacks, “Senseonics Holdings, Inc. is a medical technology company which focused on the design, development and commercialization of glucose monitoring systems. Senseonics Holdings, Inc. is based in Germantown, United States. “

Separately, Colliers Securities restated a “buy” rating on shares of Senseonics in a research report on Tuesday, March 22nd.

Shares of Senseonics stock opened at $1.33 on Friday. Senseonics has a 12-month low of $1.32 and a 12-month high of $4.58. The stock has a market capitalization of $616.14 million, a price-to-earnings ratio of -1.60 and a beta of 0.61.

Senseonics (NYSEAMERICAN:SENSGet Rating) last issued its earnings results on Tuesday, March 1st. The company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.04. The company had revenue of $4.01 million during the quarter, compared to analysts’ expectations of $4.00 million. As a group, equities research analysts anticipate that Senseonics will post -0.16 EPS for the current year.

In other Senseonics news, Director Edward Fiorentino sold 63,553 shares of Senseonics stock in a transaction on Friday, March 11th. The shares were sold at an average price of $1.65, for a total value of $104,862.45. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Nick B. Tressler sold 72,873 shares of Senseonics stock in a transaction on Friday, February 11th. The shares were sold at an average price of $2.46, for a total transaction of $179,267.58. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,020,643 shares of company stock worth $2,459,304. 5.60% of the stock is owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in SENS. US Bancorp DE raised its stake in shares of Senseonics by 28.2% in the 3rd quarter. US Bancorp DE now owns 20,466 shares of the company’s stock valued at $69,000 after acquiring an additional 4,498 shares during the period. SG Americas Securities LLC raised its stake in shares of Senseonics by 883.4% in the 3rd quarter. SG Americas Securities LLC now owns 169,215 shares of the company’s stock valued at $574,000 after acquiring an additional 152,008 shares during the period. Beck Mack & Oliver LLC purchased a new position in shares of Senseonics in the 4th quarter valued at $135,000. Kestra Advisory Services LLC raised its stake in shares of Senseonics by 70.6% in the 4th quarter. Kestra Advisory Services LLC now owns 19,335 shares of the company’s stock valued at $52,000 after acquiring an additional 8,000 shares during the period. Finally, Guild Investment Management Inc. raised its stake in shares of Senseonics by 47.1% in the 4th quarter. Guild Investment Management Inc. now owns 321,605 shares of the company’s stock valued at $859,000 after acquiring an additional 102,955 shares during the period. Institutional investors own 26.81% of the company’s stock.

Senseonics Company Profile (Get Rating)

Senseonics Holdings, Inc, a medical technology company, develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes in the United States, Europe, the Middle East, and Africa. The company's products include Eversense and Eversense XL, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management for a period of up to six months.

Recommended Stories

Get a free copy of the Zacks research report on Senseonics (SENS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Senseonics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senseonics and related companies with MarketBeat.com's FREE daily email newsletter.